Developer docs
API playgroundTry for free, no card

Search company profiles

Richter Gedeon Nyrt

Full company profile

uuid0007rup

Namestring
Richter Gedeon Nyrt
Legal namestring
Richter Gedeon Vegyészeti Gyár Nyilvánosan Működő Rt.
Company typeenum
Public
Founded yearint
1901
Descriptiontext

Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company founded in 1901 by pharmacist Gedeon Richter, listed on the Budapest Stock Exchange as a leading blue-chip. The company manufactures more than 200 drugs (originals, generics, and licensed products) across four business units: Neuropsychiatry (anchored by cariprazine/Reagila), Biotechnology (biosimilars and CDMO services through Richter BioLogics), Women's Healthcare (contraception, fertility, endometriosis, menopause, uterine fibroids, HRT), and General Medicines (cardiometabolic, CNS, rheumatology generics). It operates with 12,000+ employees, of which 1,200+ are in R&D — the largest pharmaceutical research centre in Central Eastern Europe — spending over 7% of revenue on R&D and leveraging in-house active ingredient manufacturing and internationally recognised steroid chemistry expertise.

The company sells through direct subsidiaries and representative offices in 100+ countries across Europe, CIS, Americas, Asia-Pacific, and Oceania, complemented by channel partnerships (Hikma for US biosimilars, Hetero Labs for Semaglutide in US and emerging markets, Acrux for Lenzetto in Australia, AbbVie co-development for neuropsychiatry). FY2025 revenue reached HUF 914 billion (~EUR 2.3 billion) with 14% clean EBIT growth, and FY2026 guidance points to high single-digit revenue growth. Recent strategic activity is heavily concentrated on portfolio expansion in women's healthcare (Celmatix acquisition, FimmCyte FMC2 collaboration) and entry into GLP-1 therapeutics (Semaglutide partnership with Hetero), alongside biosimilar approvals such as Tuyory's CHMP positive opinion. The company also offers CDMO services for biologics and runs a biosimilar licensing business that monetises its manufacturing scale through partners like Hikma.

Short descriptiontext

Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company (founded 1901) that manufactures 200+ drugs across neuropsychiatry, women's healthcare, biosimilars, and general medicines, selling in 100+ countries with HUF 914B FY2025 revenue.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersBudapest, Hungary
HQ citystring
Budapest
HQ countrystring
Hungary
HQ regionstring
Europe
Markets served

Serves global market

Offices18 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, biosimilar development, women's healthcare drugs, neuropsychiatry medicines, active pharmaceutical ingredients
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model4 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Richter generates revenue primarily through the manufacture and sale of pharmaceutical products including original, generic, and licensed drugs across CNS, cardiovascular, gynaecological, and general medicine therapeutic areas. The company manufactures more than 200 drugs sold in 100+ countries through direct subsidiaries and distribution partners.

gedeonrichter.com
2Licensed and Co-Development Products
TypeLicensing Royalties
Description

Revenue from licensed products (e.g., Lenzetto transdermal estradiol spray licensed to Acrux for Australia, Reagila schizophrenia treatment acquired from Recordati), and co-development partnerships including global collaboration with Hetero Labs for Semaglutide and partnership with AbbVie for neuropsychiatric treatments.

gedeonrichter.com
3CDMO / Contract Manufacturing Services
TypeManaged Services
Description

Through its biotechnology business unit, Richter offers contract development and manufacturing (CDMO) services for biosimilars and biologic products, including manufacturing denosumab biosimilars for Hikma under a 2021 license and commercialization agreement.

careers.gedeonrichter.com
4Biosimilar Licensing
TypeLicensing Royalties
Description

Revenue from out-licensing biosimilar products developed and manufactured by Richter, with Hikma holding exclusive US commercialization rights for denosumab biosimilars Enoby and Xtrenbo.

thepharmaletter.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Prescription pharmaceutical products sold through pharmacies and healthcare providers
ModelOtherBilling cadenceOther
Notes

Pharmaceutical products are priced according to national reimbursement and regulatory frameworks. No public pricing list is available.

gedeonrichter.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Enoby
Description

Denosumab biosimilar referencing Amgen's Prolia, manufactured by Gedeon Richter under Hikma license for US market.

thepharmaletter.com
+1 more record
Core offering1 text field

Richter Gedeon Nyrt is a vertically integrated specialty pharmaceutical company that manufactures and markets more than 200 drugs including original, generic, and licensed products across CNS, cardiovascular, women's healthcare, and biosimilar therapeutic areas. The company operates in-house API manufacturing, conducts original NCE research, runs CDMO services through Richter BioLogics, and distributes products to healthcare providers and patients in 100+ countries through direct subsidiaries and channel partners.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 14% growth in clean EBIT in fiscal year 2025
+1 more record
Product overview1 text field

Gedeon Richter is a Hungarian-headquartered pharmaceutical company founded in 1901, operating as a vertically integrated specialty pharmaceutical company involved in manufacturing, R&D, sales and marketing. The company manufactures more than 200 drugs including original, generic and licensed products providing effective treatments in central nervous system (CNS), cardiovascular, and gynecological (Women's Healthcare) therapeutic areas. The product portfolio is organized around four main business units: Neuropsychiatry (led by Cariprazine/Reagila), Biotechnology (including CDMO services and biosimilars), Women's Healthcare (spanning contraception, fertility, endometriosis, menopause, uterine fibroids, vaginal infections, and HRT), and General Medicines (generic medications for cardiometabolic, CNS, and rheumatology). The company's strategy emphasizes original research, women's healthcare, and biosimilars, with key products including Cariprazine for schizophrenia, Tuyory (tocilizumab biosimilar), denosumab biosimilars (Enoby/Xtrenbo), Ryeqo, and Lenzetto. Recent portfolio expansion includes acquired assets from Celmatix (fertility/endometriosis/ovarian aging programs) and partnership-enabled products like the Semaglutide generic (with Hetero Labs) and FMC2 (with FimmCyte).

Product and service7 records
1Cariprazine (Reagila)
CategoryNeuropsychiatry / CNS
Description

Cariprazine is an original research compound developed by Gedeon Richter for the treatment of central nervous system disorders, including schizophrenia and bipolar disorder. Marketed as Reagila in multiple markets.

2Lenzetto (transdermal estradiol spray)
CategoryWomen's Healthcare / Menopause / HRT
Description

Transdermal estradiol spray for menopausal hormone therapy, licensed to Acrux Limited for distribution in Australia and additional territories.

3Tuyory (tocilizumab biosimilar)
CategoryBiosimilars / Biotechnology
Description

Richter's own biosimilar tocilizumab product, branded Tuyory, intended for multiple indications corresponding to the originator biologic. Received positive CHMP opinion in 2026.

4Enoby (denosumab biosimilar)
CategoryBiosimilars / Biotechnology
Description

Denosumab biosimilar referencing Amgen's Prolia for osteoporosis treatment, manufactured by Gedeon Richter and commercialized in the US by Hikma under exclusive US commercialization rights.

5Xtrenbo (denosumab biosimilar)
CategoryBiosimilars / Biotechnology
Description

Denosumab biosimilar referencing Amgen's Xgeva for bone cancer-related complications, manufactured by Gedeon Richter and commercialized in the US by Hikma.

6Ryeqo
CategoryWomen's Healthcare / Uterine Fibroids and Endometriosis
Description

Combination therapy for symptoms of uterine fibroids and endometriosis in women of reproductive age.

7Biotechnology / CDMO Services
CategoryBiotechnology / CDMO Services
Description

Contract development and manufacturing organization (CDMO) services for biosimilars and biological drugs, delivered through Richter BioLogics GmbH in Hamburg, covering development, manufacture, and commercialization support for biologic products.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership9 partners
1Hetero Labs Ltd.
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-10
Description

Global collaboration agreement between Gedeon Richter and India-based Hetero Labs for the joint development, registration, and commercialization of Semaglutide Injection (generic version of Ozempic). The partnership combines Hetero's market reach in the US and emerging markets with Richter's commercial network across Europe and Central Asia under a cost- and profit-sharing model. Regulatory filings are planned for 2027 in the EU and US.

manufacturing.economictimes.indiatimes.com
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-27
Description

Gedeon Richter and Acrux Limited extended the license agreement dated 2 May 2013 relating to the transdermal Estradiol spray Lenzetto (menopause hormone therapy) to cover an additional commercially significant territory.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-04
Description

Richter acquired the women's health drug discovery portfolio from US biotech Celmatix, adding three early-stage programs spanning fertility, endometriosis, and ovarian aging to its pipeline. Celmatix receives upfront and milestone payments as development progresses. The deal signals ovarian biology emerging as an investable area within longevity science.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-18
Description

Swiss biotech FimmCyte entered a strategic research collaboration and option-to-license agreement with Gedeon Richter to advance its first-in-class, non-hormonal antibody treatment FMC2 for endometriosis. Joint R&D toward first-in-human clinical studies with Richter holding an exclusive option on global rights exercisable before first clinical trial. Richter operates Central Europe's largest R&D hub. FimmCyte eligible for development and commercial milestone payments plus tiered royalties.

Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-02-17
Description

Gedeon Richter UK acquired rights to the schizophrenia treatment Reagila from Recordati Pharmaceuticals, expanding the CNS portfolio in the UK market.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

AbbVie entered a co-development agreement with Gedeon Richter for novel neuropsychiatric treatments, expanding Richter's CNS pipeline through strategic partnership with a major global pharmaceutical company.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2021-01-01
Description

UK-headquartered Hikma Pharmaceuticals and its US subsidiary launched two denosumab biosimilars (Enoby and Xtrenbo) in the US market, referencing Amgen's Prolia and Xgeva. Products are manufactured by Gedeon Richter under a 2021 license and commercialization agreement, with Hikma holding exclusive US commercialization rights.

8Judit Polgár
Strategic tierMinorTypeGTM or Marketing Partner
Description

Long-standing partnership between Gedeon Richter and chess legend Judit Polgár, demonstrated at Chessparty Stockholm (April 17-18 at Avicii Arena). The partnership draws parallels between elite chess and business leadership, with thousands of children and young people attending to play chess and meet role models. Mats Jonsson, Manager of Gedeon Richter Nordics, represented the company at the event.

prnewswire.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

The Semmelweis-Richter Journalism Award 2026, jointly awarded by Semmelweis University and Gedeon Richter, recognises outstanding journalism on health topics in Europe. Total prize of 45,000 EUR across two categories (Women's Health and Pharma Strategies and Innovation). Winners to be announced in the last week of July 2026.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries44 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Richter Gedeon Nyrt

Specialty Pharmaceuticalsgedeonrichter.com

Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company (founded 1901) that manufactures 200+ drugs across neuropsychiatry, women's healthcare, biosimilars, and general medicines, selling in 100+ countries with HUF 914B FY2025 revenue.

What Richter Gedeon Nyrt does

Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company founded in 1901 by pharmacist Gedeon Richter, listed on the Budapest Stock Exchange as a leading blue-chip. The company manufactures more than 200 drugs (originals, generics, and licensed products) across four business units: Neuropsychiatry (anchored by cariprazine/Reagila), Biotechnology (biosimilars and CDMO services through Richter BioLogics), Women's Healthcare (contraception, fertility, endometriosis, menopause, uterine fibroids, HRT), and General Medicines (cardiometabolic, CNS, rheumatology generics). It operates with 12,000+ employees, of which 1,200+ are in R&D — the largest pharmaceutical research centre in Central Eastern Europe — spending over 7% of revenue on R&D and leveraging in-house active ingredient manufacturing and internationally recognised steroid chemistry expertise.

The company sells through direct subsidiaries and representative offices in 100+ countries across Europe, CIS, Americas, Asia-Pacific, and Oceania, complemented by channel partnerships (Hikma for US biosimilars, Hetero Labs for Semaglutide in US and emerging markets, Acrux for Lenzetto in Australia, AbbVie co-development for neuropsychiatry). FY2025 revenue reached HUF 914 billion (~EUR 2.3 billion) with 14% clean EBIT growth, and FY2026 guidance points to high single-digit revenue growth. Recent strategic activity is heavily concentrated on portfolio expansion in women's healthcare (Celmatix acquisition, FimmCyte FMC2 collaboration) and entry into GLP-1 therapeutics (Semaglutide partnership with Hetero), alongside biosimilar approvals such as Tuyory's CHMP positive opinion. The company also offers CDMO services for biologics and runs a biosimilar licensing business that monetises its manufacturing scale through partners like Hikma.

Richter Gedeon Nyrt firmographics

Firmographics
Name
Richter Gedeon Nyrt
Legal name
Richter Gedeon Vegyészeti Gyár Nyilvánosan Működő Rt.
Website
https://gedeonrichter.com
Company type
Public
Founded year
1901
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Richter Gedeon Nyrt. is a Hungary-headquartered, vertically integrated specialty pharmaceutical company (founded 1901) that manufactures 200+ drugs across neuropsychiatry, women's healthcare, biosimilars, and general medicines, selling in 100+ countries with HUF 914B FY2025 revenue.
Ownership category
akta.pro rank

Richter Gedeon Nyrt industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAGABAC
Biologics (mAbs/Recombinant Proteins) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAAAF
Neurology & Psychiatry (CNS) Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

  • Specialty pharmaceuticals
  • Biosimilar development
  • Women's healthcare drugs
  • Neuropsychiatry medicines
  • Active pharmaceutical ingredients

Where Richter Gedeon Nyrt is headquartered

Location

Headquarters

HQ city
Budapest
HQ country
Hungary
HQ region
Europe

Offices18 records

Markets served

Richter Gedeon Nyrt business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Richter generates revenue primarily through the manufacture and sale of pharmaceutical products including original, generic, and licensed drugs across CNS, cardiovascular, gynaecological, and general medicine therapeutic areas. The company manufactures more than 200 drugs sold in 100+ countries through direct subsidiaries and distribution partners.
  2. Licensed and Co-Development Products: Revenue from licensed products (e.g., Lenzetto transdermal estradiol spray licensed to Acrux for Australia, Reagila schizophrenia treatment acquired from Recordati), and co-development partnerships including global collaboration with Hetero Labs for Semaglutide and partnership with AbbVie for neuropsychiatric treatments.
  3. CDMO / Contract Manufacturing Services: Through its biotechnology business unit, Richter offers contract development and manufacturing (CDMO) services for biosimilars and biologic products, including manufacturing denosumab biosimilars for Hikma under a 2021 license and commercialization agreement.
  4. Biosimilar Licensing: Revenue from out-licensing biosimilar products developed and manufactured by Richter, with Hikma holding exclusive US commercialization rights for denosumab biosimilars Enoby and Xtrenbo.

Pricing tiers

ModelBillingPrice
OtherOtherPrescription pharmaceutical products sold through pharmacies and healthcare providers

Go-to-market motion3 records

Distribution channels5 records

Marketing channels4 records

Richter Gedeon Nyrt product offering

Product offering

Core offering

Richter Gedeon Nyrt is a vertically integrated specialty pharmaceutical company that manufactures and markets more than 200 drugs including original, generic, and licensed products across CNS, cardiovascular, women's healthcare, and biosimilar therapeutic areas. The company operates in-house API manufacturing, conducts original NCE research, runs CDMO services through Richter BioLogics, and distributes products to healthcare providers and patients in 100+ countries through direct subsidiaries and channel partners.

Product overview

Gedeon Richter is a Hungarian-headquartered pharmaceutical company founded in 1901, operating as a vertically integrated specialty pharmaceutical company involved in manufacturing, R&D, sales and marketing. The company manufactures more than 200 drugs including original, generic and licensed products providing effective treatments in central nervous system (CNS), cardiovascular, and gynecological (Women's Healthcare) therapeutic areas. The product portfolio is organized around four main business units: Neuropsychiatry (led by Cariprazine/Reagila), Biotechnology (including CDMO services and biosimilars), Women's Healthcare (spanning contraception, fertility, endometriosis, menopause, uterine fibroids, vaginal infections, and HRT), and General Medicines (generic medications for cardiometabolic, CNS, and rheumatology). The company's strategy emphasizes original research, women's healthcare, and biosimilars, with key products including Cariprazine for schizophrenia, Tuyory (tocilizumab biosimilar), denosumab biosimilars (Enoby/Xtrenbo), Ryeqo, and Lenzetto. Recent portfolio expansion includes acquired assets from Celmatix (fertility/endometriosis/ovarian aging programs) and partnership-enabled products like the Semaglutide generic (with Hetero Labs) and FMC2 (with FimmCyte).

Differentiator

Problem solved

Functional benefit

Brands

  • Enoby: Denosumab biosimilar referencing Amgen's Prolia, manufactured by Gedeon Richter under Hikma license for US market.
  • Xtrenbo

Products and services

  • Cariprazine (Reagila) Cariprazine is an original research compound developed by Gedeon Richter for the treatment of central nervous system disorders, including schizophrenia and bipolar disorder. Marketed as Reagila in multiple markets.
  • Lenzetto (transdermal estradiol spray) Transdermal estradiol spray for menopausal hormone therapy, licensed to Acrux Limited for distribution in Australia and additional territories.
  • Tuyory (tocilizumab biosimilar) Richter's own biosimilar tocilizumab product, branded Tuyory, intended for multiple indications corresponding to the originator biologic. Received positive CHMP opinion in 2026.
  • Enoby (denosumab biosimilar) Denosumab biosimilar referencing Amgen's Prolia for osteoporosis treatment, manufactured by Gedeon Richter and commercialized in the US by Hikma under exclusive US commercialization rights.
  • Xtrenbo (denosumab biosimilar) Denosumab biosimilar referencing Amgen's Xgeva for bone cancer-related complications, manufactured by Gedeon Richter and commercialized in the US by Hikma.
  • Ryeqo Combination therapy for symptoms of uterine fibroids and endometriosis in women of reproductive age.
  • Biotechnology / CDMO Services Contract development and manufacturing organization (CDMO) services for biosimilars and biological drugs, delivered through Richter BioLogics GmbH in Hamburg, covering development, manufacture, and commercialization support for biologic products.

Quantifiable outcome

  • 14% growth in clean EBIT in fiscal year 2025
  • +1 more outcomes

Companies that use Richter Gedeon Nyrt

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Richter Gedeon Nyrt technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Richter Gedeon Nyrt partnerships and signals

Strategic signal

Partnerships

Nine partnerships are on record, tiered core and minor.

  • Hetero Labs Ltd.coreStrategic or Co-development Partner · 10 June 2026Global collaboration agreement between Gedeon Richter and India-based Hetero Labs for the joint development, registration, and commercialization of Semaglutide Injection (generic version of Ozempic). The partnership combines Hetero's market reach in the US and emerging markets with Richter's commercial network across Europe and Central Asia under a cost- and profit-sharing model. Regulatory filings are planned for 2027 in the EU and US.
  • Acrux LimitedminorChannel Partner/ Reseller/ Distributor · 27 May 2026Gedeon Richter and Acrux Limited extended the license agreement dated 2 May 2013 relating to the transdermal Estradiol spray Lenzetto (menopause hormone therapy) to cover an additional commercially significant territory.
  • CelmatixcoreStrategic or Co-development Partner · 4 March 2026Richter acquired the women's health drug discovery portfolio from US biotech Celmatix, adding three early-stage programs spanning fertility, endometriosis, and ovarian aging to its pipeline. Celmatix receives upfront and milestone payments as development progresses. The deal signals ovarian biology emerging as an investable area within longevity science.
  • FimmCytecoreStrategic or Co-development Partner · 18 February 2026Swiss biotech FimmCyte entered a strategic research collaboration and option-to-license agreement with Gedeon Richter to advance its first-in-class, non-hormonal antibody treatment FMC2 for endometriosis. Joint R&D toward first-in-human clinical studies with Richter holding an exclusive option on global rights exercisable before first clinical trial. Richter operates Central Europe's largest R&D hub. FimmCyte eligible for development and commercial milestone payments plus tiered royalties.
  • Recordati PharmaceuticalsminorChannel Partner/ Reseller/ Distributor · 17 February 2026Gedeon Richter UK acquired rights to the schizophrenia treatment Reagila from Recordati Pharmaceuticals, expanding the CNS portfolio in the UK market.
  • AbbViecoreStrategic or Co-development Partner · 1 January 2024AbbVie entered a co-development agreement with Gedeon Richter for novel neuropsychiatric treatments, expanding Richter's CNS pipeline through strategic partnership with a major global pharmaceutical company.
  • Hikma PharmaceuticalscoreChannel Partner/ Reseller/ Distributor · 1 January 2021UK-headquartered Hikma Pharmaceuticals and its US subsidiary launched two denosumab biosimilars (Enoby and Xtrenbo) in the US market, referencing Amgen's Prolia and Xgeva. Products are manufactured by Gedeon Richter under a 2021 license and commercialization agreement, with Hikma holding exclusive US commercialization rights.
  • Judit PolgárminorGTM or Marketing PartnerLong-standing partnership between Gedeon Richter and chess legend Judit Polgár, demonstrated at Chessparty Stockholm (April 17-18 at Avicii Arena). The partnership draws parallels between elite chess and business leadership, with thousands of children and young people attending to play chess and meet role models. Mats Jonsson, Manager of Gedeon Richter Nordics, represented the company at the event.
  • Semmelweis UniversityminorGTM or Marketing PartnerThe Semmelweis-Richter Journalism Award 2026, jointly awarded by Semmelweis University and Gedeon Richter, recognises outstanding journalism on health topics in Europe. Total prize of 45,000 EUR across two categories (Women's Health and Pharma Strategies and Innovation). Winners to be announced in the last week of July 2026.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Richter Gedeon Nyrt competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat6 records

Key risks5 records

Key highlights6 records

Customer concentration

Richter Gedeon Nyrt social profiles

Digital presence

Richter Gedeon Nyrt financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Richter Gedeon Nyrt leadership team

Management profile

Number of profiles

Profiles7 records

Richter Gedeon Nyrt subsidiaries and ownership

Company hierarchy

Subsidiaries44 records

Richter Gedeon Nyrt funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Richter Gedeon Nyrt M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Richter Gedeon Nyrt

What does Richter Gedeon Nyrt do?

Richter Gedeon Nyrt is a vertically integrated specialty pharmaceutical company that manufactures and markets more than 200 drugs including original, generic, and licensed products across CNS, cardiovascular, women's healthcare, and biosimilar therapeutic areas. The company operates in-house API manufacturing, conducts original NCE research, runs CDMO services through Richter BioLogics, and distributes products to healthcare providers and patients in 100+ countries through direct subsidiaries and channel partners.

Is Richter Gedeon Nyrt a public or private company?

Richter Gedeon Nyrt is a public company. It is classified as public and is currently operating.

When was Richter Gedeon Nyrt founded?

Richter Gedeon Nyrt was founded in 1901. It employs 1,001 to 5,000 people.

Where is Richter Gedeon Nyrt based?

Richter Gedeon Nyrt is headquartered in Budapest, Hungary, in the Europe region.

How does Richter Gedeon Nyrt make money?

Four revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensed and Co-Development Products, CDMO / Contract Manufacturing Services and biosimilar Licensing.

Does Richter Gedeon Nyrt have an API?

No public API is recorded for Richter Gedeon Nyrt.

What industry is Richter Gedeon Nyrt in?

Richter Gedeon Nyrt's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO. Its NAICS code is 32541 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Nate헝가리 게데온 리히터, 호주 메인파마 4억800만 달러에 인수 추진 : 네이트 뉴스Hungarian pharmaceutical giant Gedeon Richter agreed to acquire Australian firm Mayne Pharma for about $480 million, causing Mayne's stock to surge 86% to $5.97. The deal, valued at $640 million, requires shareholder and regulatory approval, with completion expected by mid-2027.The future of tradingAustralia's Mayne Pharma surges on $408 million takeover by Hungary's Gedeon RichterMayne Pharma shares surged up to 86% to A$5.970 after Gedeon Richter entered a takeover scheme to buy 100% of the company. The offer values equity at about A$604 million, a 99.4% premium to the last close, subject to selling its international business to Evaris Pharma.Dealroom.coGedeon Richter to buy Mayne Pharma in US$390.8M cash deal at 99% premium | Dealroom NewsGedeon Richter agreed to acquire ASX-listed Mayne Pharma for US$4.14 per share in cash, valuing the company at about US$390.8M. The deal represents a 99.4% premium to Mayne's November 16 close, with shareholders representing 22.14% voting in favor. Implementation is targeted for early 2027.TradingViewMayne Pharma Agrees to $604m Takeover Proposal from Gedeon RichterMayne Pharma agreed to a $604 million cash takeover by Gedeon Richter, offering $6.40 per share, a 99.4% premium to the closing price. The deal depends on completing the sale of its International business to Evaris Pharma and obtaining regulatory approvals. Shareholder voting is scheduled for late January 2027.TradingViewMYX: A$6.40 cash Scheme offers a 99.4% premium, pending approvalsGedeon Richter proposes an all-cash acquisition of Mayne Pharma at A$6.40 per share, a 99.4% premium to the 16 Nov 2026 closing price. The Board unanimously recommends the scheme, subject to conditions, with implementation expected in March 2027.The future of tradingAustralia's Mayne Pharma accepts $408 million bid from Gedeon RichterMayne Pharma accepted a $408 million bid from Gedeon Richter, valuing the deal at about A$604 million. Gedeon Richter offered A$6.40 per Mayne share. The acquisition was agreed on Tuesday.LechoLe sens des affaires | Dans les sciences du vivant, rien n'est jamais totalement perduMithra's two products, developed by the Liège-based company, continue to be marketed under Gedeon Richter and soon Eli Lilly. The Hungarian group has retained its R&D team in Liège.The Pharma LetterLilly enters deal with Gedeon Richter for E4 platformEli Lilly received exclusive worldwide rights to develop, manufacture, and commercialize medicines combining Gedeon Richter's E4 with Lilly compounds for women's health and cardiometabolic disease. Richter receives an undisclosed upfront payment and is eligible for regulatory and commercial milestones plus tiered royalties on net sales.The Pharma LetterFDA accepts NDA for Richter’s Fylrevy for reviewThe FDA accepted Gedeon Richter's NDA for Fylrevy, an estrogen therapy for menopausal vasomotor symptoms, for review. The review is expected to conclude by the third quarter of 2027, and if approved, Fylrevy would be the first E4-based menopausal hormone therapy on the US market.FinanzNachrichten.deGedeon Richter stellt auf der "Next Step"-Konferenz eine Online-Plattform für transdiagnostische Global-Impression-Skalen und ein neues Buch für Betreuende vorGedeon Richter hosted its Next Step conference in Budapest, presenting an online platform for transdiagnostic Global Impression scales and The Candid Book 3 on sexual health. The platform is available at Richter TGI Scales, and the book offers practical guidance for caregivers.